立体定向消融放疗挽救性治疗非小细胞肺癌孤立性肺复发:一项II期临床试验的长期结局
这项II期临床试验前瞻性纳入59例经根治性治疗后组织学确认、PET分期的孤立性NSCLC肺实质复发(≤3 cm)患者,接受50 Gy/4次容积调强影像引导SABR。中位随访58.3个月,5年局部、区域、远处失败率分别为5.2%、10.3%、22.4%,5年OS 56.5%、PFS 41.1%,3级不良事件3例(5%),无4-5级事件。
要点
- 挽救性SABR后5年OS 56.5%、PFS 41.1%,局部失败率5.2%。
- 3级治疗相关不良事件3例(5%),无4级或5级事件。
- SABR后中性粒细胞与淋巴细胞比值高预测生存差。
核心结论
- 挽救性SABR对孤立性NSCLC肺实质复发提供优异的5年OS、局部控制和PFS,毒性极小。
- 结果与早期原发性NSCLC根治性SABR的历史报告结局相当。
- SABR似乎是根治性治疗后孤立性肺实质复发患者非常有效且安全的挽救选择,作者认为应与手术一同考虑作为局部肺实质复发患者的潜在一线选择。
研究设计与样本
- 前瞻性II期临床试验,纳入组织学确认、PET分期的孤立性NSCLC局部或肺实质转移复发(≤3 cm,适合SABR)且既往接受根治性治疗的患者。
- 治疗方案为容积调强、影像引导SABR,50 Gy分4次。
- 共59例复发患者接受挽救性SABR,中位年龄70岁(范围45-86岁),挽救性SABR后中位随访58.3个月。
- 主要终点包括挽救性SABR后的失败模式、总生存(OS)和无进展生存(PFS)。
主要发现
- 挽救性SABR后19例(32%)出现再复发。
- 自挽救性SABR日期起,估计5年局部、区域和远处失败率分别为5.2%、10.3%和22.4%。
- 估计PFS 3年为46.2%、5年为41.1%;OS 3年为63.5%、5年为56.5%。
- SABR后中性粒细胞与淋巴细胞比值高预测生存差。
- 3级治疗相关不良事件3例(5%),无4级或5级事件。
关键数值与推荐
- 复发灶大小≤3 cm且适合SABR。
- SABR剂量50 Gy分4次。
临床怎么用
- 作者认为SABR应与手术一同考虑作为局部肺实质复发患者的潜在一线选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our goal was to evaluate stereotactic ablative radiotherapy (SABR) as a salvage option for isolated recurrence of NSCLC in the lung parenchyma after definitive treatment of stage I to III disease. METHODS: Patients who had histologically confirmed, positron emission tomography-staged, isolated NSCLC recurring locally or metastasis in the lung parenchyma (≤3 cm, suitable for SABR) after previous definitive treatment were prospectively enrolled in this trial and treated with volumetric, image-guided SABR to 50 Gy in four fractions. Patients were then followed with computed tomography or positron emission tomography/computed tomography. Primary end points included the pattern of failure after salvage SABR, overall survival (OS), and progression-free survival (PFS). RESULTS: Fifty-nine patients with recurrent disease were treated with salvage SABR. The median age was 70 years (range 45-86 years), and the median follow-up time after salvage SABR was 58.3 months. Re-recurrence after salvage SABR developed in 19 patients (32%). Measuring from the date of salvage SABR, the estimated 5-year rates of local, regional, and distant failure were 5.2%, 10.3%, and 22.4%, respectively; the estimated PFS was 46.2% at 3 years and 41.1% at 5 years; and the OS rates were 63.5% at 3 years and 56.5% at 5 years. A high post-SABR neutrophil-to-lymphocyte ratio was found to predict poor survival. Grade 3 treatment-related adverse events developed in three patients (5%). No patient had a grade 4 or 5 event. CONCLUSION: Our study showed that salvage SABR provides excellent 5-year OS, local control, and PFS rates with minimal toxicity for patients with isolated NSCLC recurrence in the lung parenchyma. These results are striking and comparable to historically reported outcomes of patients with primary early-stage NSCLC treated with definitive SABR. SABR appears to be a very effective and safe salvage option for patients with isolated lung parenchyma recurrent disease after definitive treatment and should be considered along with surgery as a potential first-line option for patients with local lung parenchymal recurrent disease.
引用
- Sun B, Brooks ED, Komaki R, et al. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017. PMID: 28259750. doi:10.1016/j.jtho.2017.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。